87 results
8-K
EX-99.1
VIR
Vir Biotechnology Inc
2 May 24
Vir Biotechnology Provides Corporate Update and Reports First Quarter 2024 Financial Results
4:09pm
supported in part with federal funds from the Department of Health and Human Services (HHS); Administration for Strategic Preparedness and Response … using Vir’s proprietary monoclonal antibody discovery platform.
The PENINSULA trial has been supported in part with federal funds from the Department
8-K
EX-99.1
VIR
Vir Biotechnology Inc
18 Apr 24
Vir Biotechnology Announces Nomination of Norbert Bischofberger, Ph.D. and Ramy
8:44am
professor in the chemistry department at Rutgers University. He was a National Institutes of Health postdoctoral fellow in the Department
8-K
EX-99.1
h85fmoslk0ng447vov
22 Feb 24
Vir Biotechnology Provides Corporate Update and Reports Fourth Quarter and Full Year 2023 Financial Results
4:12pm
S-3ASR
EX-1.2
bqx1vfltxg8 ejifo
3 Nov 23
Automatic shelf registration
4:33pm
8-K
EX-99.1
wea5thm o3fa
2 Nov 23
Vir Biotechnology Provides Corporate Update and Reports Third Quarter 2023 Financial Results
4:09pm
8-K
t4twkh5
3 Oct 23
Entry into a Material Definitive Agreement
8:01am
8-K
EX-99.1
flzx vc3di
3 Aug 23
Vir Biotechnology Provides Corporate Update and Reports Second Quarter 2023 Financial Results
4:14pm
8-K
EX-99.1
ci1vwrh 7bl5cmsbqd
20 Jul 23
Vir Biotechnology Announces Topline Data from Phase 2 PENINSULA Trial Evaluating
8:04am
8-K
zbuwzf67vt069 pg
20 Jul 23
Vir Biotechnology Announces Topline Data from Phase 2 PENINSULA Trial Evaluating
8:04am
8-K
EX-99.1
qqe5i5tere35jbu
4 May 23
Vir Biotechnology Provides Corporate Update and Reports First Quarter 2023 Financial Results
4:16pm